Icure Pharmaceutical (XKRX:175250) 3-Year Revenue Growth Rate : -26.70% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical 3-Year Revenue Growth Rate?

Icure Pharmaceutical's Revenue per Share for the three months ended in Mar. 2024 was ₩423.50.

During the past 12 months, Icure Pharmaceutical's average Revenue per Share Growth Rate was -23.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -26.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Icure Pharmaceutical was 19.50% per year. The lowest was -26.70% per year. And the median was 8.40% per year.

Competitive Comparison of Icure Pharmaceutical's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icure Pharmaceutical's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's 3-Year Revenue Growth Rate falls into.

Icure Pharmaceutical 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Icure Pharmaceutical (XKRX:175250) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Icure Pharmaceutical 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical (XKRX:175250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical (XKRX:175250) Headlines

No Headlines